---
layout: default
title: Alpha -Tocopherol Acetate D- Ascorbic Acid Choleca
parent: 僅模型預測 (L5)
nav_order: 219
evidence_level: L5
indication_count: 0
---

# Alpha -Tocopherol Acetate D- Ascorbic Acid Choleca
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Vitamin/Mineral Complex (Prenatal Supplement): Insufficient Data for Repurposing Analysis

## One-Sentence Summary

This entry represents a **multi-component nutritional supplement** containing 15 active ingredients — including omega-3 fatty acids (DHA/EPA), multiple B-vitamins, folate forms, Vitamin C/D/E, and essential minerals — consistent with a prenatal or comprehensive nutritional formula.
The TxGNN model was **unable to generate repurposing predictions** for this entry, as the multi-component INN string could not be resolved to a single DrugBank entity.
**No clinical trial or publication evidence** is linked to this candidate in the current dataset.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available (no regulatory record found) |
| Predicted New Indication | No predictions generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only; no actual predictions generated |
| US Market Status | Not Marketed (no approvals on record) |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

This candidate was submitted as a **single INN string containing 15 co-listed active ingredients**:

| # | Ingredient | Category |
|---|-----------|---------|
| 1 | D-Alpha-Tocopherol Acetate | Vitamin E |
| 2 | Ascorbic Acid | Vitamin C |
| 3 | Cholecalciferol | Vitamin D3 |
| 4 | Cyanocobalamin | Vitamin B12 |
| 5 | Doconexent (DHA) | Omega-3 fatty acid |
| 6 | Folic Acid | B9 (inactive form) |
| 7 | Icosapent (EPA) | Omega-3 fatty acid |
| 8 | Iron Pentacarbonyl | Mineral — Iron |
| 9 | Levomefolate Magnesium | B9 (active form) |
| 10 | Magnesium Oxide | Mineral — Magnesium |
| 11 | Niacin | Vitamin B3 |
| 12 | Potassium Iodide | Mineral — Iodine |
| 13 | Pyridoxine Hydrochloride | Vitamin B6 |
| 14 | Riboflavin | Vitamin B2 |
| 15 | Thiamine | Vitamin B1 |

The TxGNN knowledge graph operates at the **single-entity level**: each prediction requires one DrugBank ID mapped to one drug node. Because no DrugBank ID could be resolved from this compound INN string, the pipeline had no graph node to anchor a repurposing traversal, resulting in zero predictions.

This profile is consistent with a **prenatal multivitamin** formulation (note: dual folate forms — folic acid + levomefolate; DHA/EPA for fetal neurodevelopment; iodine for thyroid function during pregnancy). Such combination products are typically regulated as nutritional supplements rather than prescription drugs, which also explains the absence of NDA records.

---

## Safety Considerations

No safety data is available for this candidate at the combination-product level. For individual ingredient safety, please refer to the respective package inserts or DrugBank entries for each component.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The pipeline failed at the entity-resolution step — the multi-component INN string could not be linked to a DrugBank node, making TxGNN prediction structurally impossible for this entry as submitted. There is nothing clinically actionable to evaluate.

**To proceed, the following is needed:**

- **Decompose the submission**: Split the 15 co-listed ingredients into individual INN entries and re-run each through the pipeline separately (e.g., Doconexent, Icosapent, Folic Acid each as standalone candidates).
- **Identify the intended product**: Confirm whether this is a specific branded prenatal product and look up its NDA/ANDA directly (e.g., FDA Orange Book search for prenatal vitamins with DHA).
- **Correct the candidate ID**: The `candidate_id` is listed as `TW-UNKNOWN-multi`, suggesting a data ingestion anomaly — investigate upstream data source for parsing errors on multi-component INN fields.
- **Evaluate individually high-interest components**: Doconexent (DHA) and Icosapent (EPA) both have independent TxGNN-eligible DrugBank IDs and active repurposing research (e.g., cardiovascular, neurological indications); these warrant separate evaluation.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

